Universal, glycosylation enhancer, completely chemically defined medium formulation

    公开(公告)号:US10119117B2

    公开(公告)日:2018-11-06

    申请号:US15404007

    申请日:2017-01-11

    IPC分类号: C12N5/00

    摘要: In one embodiment, the present application discloses a cell culture medium for culturing cell lines suitable for producing a therapeutic protein, comprising an amino acid selected from a group consisting of L-arginine, L-asparagine, L-proline, L leucine and L hydroxyproline and a mixture thereof; a vitamin selected from a group consisting of ascorbic acid Mg2+ salt, biotin, pyridoxine HCL, folic acid, riboflavin and D-calcium pantothenate, and a mixture thereof; an element selected from a group consisting of ammonium meta vanadate, sodium meta vanadate, germanium dioxide, barium acetate, aluminum chloride, rubidium chloride, cadmium chloride, ammonium molybedate, stannous chloride, cobalt chloride, chromium sulfate, silver nitrate, sodium metasilicate, zinc sulfate, manganese sulfate H2O, manganous chloride, ferric nitrate 9H2O, ferrous sulfate 7H2O, ferric ammonium citrate, magnesium chloride anhydrous, and magnesium sulfate anhydrous, and a mixture thereof; a nucleoside selected from a group consisting of uridine and cystidine; a sugar selected from a group consisting of galactose, mannose and N-Acetyl-D-Mannosamine; and a triple buffering system comprising sodium carbonate, sodium bicarbonate and HEPES; wherein the cell culture medium is animal component-free, plant component-free, serum-free, growth factors-free, recombinant protein-free, lipid-free, steroid-free, and free of plant or animal hydrolysates and/or extracts.

    PEG-interferon lambda 1 conjugates
    2.
    发明授权
    PEG-interferon lambda 1 conjugates 有权
    PEG-干扰素λ1缀合物

    公开(公告)号:US08454947B1

    公开(公告)日:2013-06-04

    申请号:US13409946

    申请日:2012-03-01

    申请人: Nhan Ho

    发明人: Nhan Ho

    IPC分类号: A61K38/21 C07K14/555

    摘要: The present application discloses new PEG-interferon lambda 1 conjugates (PEG-IFNλ1), processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to IFNλ1 and are effective in the treatment of hepatitis B and hepatitis C.

    摘要翻译: 本申请公开了新的PEG-干扰素λ1缀合物(PEG-IFNλ1),其制备方法,含有这些缀合物的药物组合物及其制备方法。 这些缀合物与IFN-λ1相比具有增加的血液半衰期和持续时间,并且在治疗乙型肝炎和丙型肝炎方面是有效的。

    3-deoxypentopyranosyl nucleic acid, its production and its use
    3.
    发明授权
    3-deoxypentopyranosyl nucleic acid, its production and its use 失效
    3-脱氧吡喃糖基核酸,其生产及其应用

    公开(公告)号:US07700761B2

    公开(公告)日:2010-04-20

    申请号:US11445037

    申请日:2006-05-31

    IPC分类号: C07H21/00 C07H19/04

    摘要: Provided are processes for preparing a 3′-deoxypentopyranosyl oligomers with linkers for linking biomolecules. The processes can the steps of: bonding a 4′-protected-3′-deoxypentopyranosyl nucleoside to a solid support by coupling the 2′-OH group with a CPG support or other similar support with an amide linkage; deprotecting the 4′-protected-3′-deoxypentopyranosyl nucleoside at the 4′ position; deprotecting the 4′-protected-3′-deoxypentopyranosyl nucleoside at the 4′ position; and conjugating a linker to the free 4′ position. The resulting product can be conjugated via the linker to a biomolecule. The method can include, prior to addition of the linker, reacting the 4′-OH group of the 4′-protected-3′-deoxypentopyranosyl nucleoside that is linked to the solid support with a 4′-protected-3′-deoxypentopyranosyl nucleoside phosphoramidite in the presence of a coupling reagent, and oxidizing the reaction product. This step can be repeated one or more times to produce an oligomer of desired length.

    摘要翻译: 提供制备具有用于连接生物分子的接头的3'-脱氧吡喃糖基寡聚物的方法。 该方法可以通过以下步骤:通过将2'-OH基团与CPG载体或其它类似载体与酰胺键偶联,将4'-保护的-3'-脱氧吡喃糖基核苷键合到固体支持物上; 在4'位保护4'-保护的3'-脱氧吡喃糖基核苷; 在4'位保护4'-保护的3'-脱氧吡喃糖基核苷; 并将接头缀合到游离的4'位置。 所得产物可通过接头与生物分子结合。 该方法可以包括在加入连接体之前,将与固体支持物连接的4'-保护的3'-脱氧吡喃糖基核苷的4'-OH基团与4'-保护的-3'-脱氧吡喃糖基核苷 亚磷酰胺在偶联剂存在下反应,氧化反应产物。 该步骤可以重复一次或多次以制备所需长度的低聚物。

    Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
    4.
    发明授权
    Method for diagnosing and distinguishing stroke and diagnostic devices for use therein 有权
    用于诊断和区分用于其中的卒中和诊断装置的方法

    公开(公告)号:US07655424B2

    公开(公告)日:2010-02-02

    申请号:US10924283

    申请日:2004-08-23

    申请人: George Jackowski

    发明人: George Jackowski

    IPC分类号: G01N33/00 G01N33/543

    CPC分类号: G01N33/6896 G01N2800/2871

    摘要: A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

    摘要翻译: 一种用于确定受试者是否具有中风的方法,如果是,则包括分析至少四种选择的中风标志物的主体体液的中风类型,即髓磷脂碱性蛋白,S100蛋白,神经元特异性烯醇化酶和 脑内皮细胞膜蛋白如血栓调节蛋白或类似分子。 从分析获得的数据提供关于中风类型,发生发生和脑损伤程度的信息,并允许医生快速确定受试者所需的治疗类型。

    Apolipoprotein biopolymer markers indicative of insulin resistance
    6.
    发明授权
    Apolipoprotein biopolymer markers indicative of insulin resistance 失效
    指示胰岛素抵抗的载脂蛋白生物聚合物标记物

    公开(公告)号:US07314762B2

    公开(公告)日:2008-01-01

    申请号:US09993366

    申请日:2001-11-21

    IPC分类号: G01N33/543

    CPC分类号: C07K14/775

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样的样品中验证的生物聚合物队列参考其至少证明特定疾病状态的能力; 从而使得诊断医生能够获得表征存在或不存在至少一种疾病状态的能力,相对于识别生物聚合物的存在和/或不存在,预测疾病风险评估以及开发针对该疾病的治疗途径。

    Programmable multiplexed active biologic array
    7.
    发明授权
    Programmable multiplexed active biologic array 有权
    可编程多路复用活性生物阵列

    公开(公告)号:US07267751B2

    公开(公告)日:2007-09-11

    申请号:US10224750

    申请日:2002-08-20

    摘要: The present invention is directed to devices and methods for carrying out and/or monitoring biological reactions in response to electrical stimuli. A programmable multiplexed active biologic array includes an array of electrodes coupled to sample-and-hold circuits. The programmable multiplexed active biologic array includes a digital interface that allows external control of the array using an external processor. The circuit may monitor, digitally control, and deliver electrical stimuli to the electrodes individually or in selected groups.

    摘要翻译: 本发明涉及用于响应于电刺激进行和/或监测生物反应的装置和方法。 可编程复用的有源生物阵列包括耦合到采样和保持电路的电极阵列。 可编程复用的有源生物阵列包括允许使用外部处理器对阵列进行外部控制的数字接口。 该电路可以单独或选定的组监测,数字控制和传递对电极的电刺激。